<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672773</url>
  </required_header>
  <id_info>
    <org_study_id>18-001387</org_study_id>
    <secondary_id>NCI-2018-01409</secondary_id>
    <secondary_id>TRIO-US L-07</secondary_id>
    <nct_id>NCT03672773</nct_id>
  </id_info>
  <brief_title>Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how effective talazoparib and temozolomide are for treating&#xD;
      participants with extensive-stage small cell lung cancer that has come back after an initial&#xD;
      chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by&#xD;
      preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide&#xD;
      may work better in treating participants with extensive-stage small cell lung cancer than&#xD;
      either one alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the efficacy of talazoparib in combination with temozolomide as measured by&#xD;
      objective response rate (ORR).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the efficacy of talazoparib plus temozolomide as measured by progression-free&#xD;
      survival (PFS), overall survival, duration of response, and time to response.&#xD;
&#xD;
      II. To evaluate the safety, tolerability of talazoparib plus temozolomide. III. To evaluate&#xD;
      the pharmacokinetics of talazoparib when given in combination with temozolomide.&#xD;
&#xD;
      IV. To evaluate patient reported outcomes per the Patient Reported Outcomes version of the&#xD;
      Common Terminology Criteria for Adverse Events (PRO-CTCAE).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To identify potential biomarkers associated with response to study drug treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive temozolomide orally (PO) on days 1-5 and talazoparib PO once daily (QD)&#xD;
      on days 1-28. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 30 days and then up to 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIS)T 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be provided along with the corresponding exact 2-sided 95% confidence interval calculated using a method based on the F distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) assessed by RECIST 1.1</measure>
    <time_frame>From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year</time_frame>
    <description>Will be summarized for the safety analysis (SA) set. Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by RECIST 1.1</measure>
    <time_frame>From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year</time_frame>
    <description>Will be summarized for the SA set. Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate. Median event times and 2-sided 95% confidence interval for each median will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From treatment initiation to death by any cause, assessed up to 1 year</time_frame>
    <description>Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (CR or PR) per RECIST 1.1</measure>
    <time_frame>From the first documentation of objective tumor response, assessed up to 1 year</time_frame>
    <description>Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (CR or PR) per RECIST 1.1</measure>
    <time_frame>From treatment initiation to the first documentation of objective tumor response, assessed up to 1 year</time_frame>
    <description>Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of talazoparib - steady state trough plasma concentrations</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To evaluate the pharmacokinetics (steady state trough plasma concentrations) of talazoparib when given in combination with temozolomide</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Recurrent Extensive Stage Small Cell Lung Carcinoma</condition>
  <condition>Refractory Extensive Stage Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (temozolomide, talazoparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (temozolomide, talazoparib)</arm_group_label>
    <other_name>BMN 673</other_name>
    <other_name>BMN-673</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (temozolomide, talazoparib)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
          -  Cytologically or histologically confirmed small cell lung cancer (SCLC) with&#xD;
             extensive-stage disease.&#xD;
&#xD;
          -  Relapsed (progressed within 6 months) or refractory (progressed during or within 4&#xD;
             weeks of completing 1st line platinum based regimen).&#xD;
&#xD;
          -  Measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
          -  Archival or fresh tissue biopsy available for exploratory analyses.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 1.&#xD;
&#xD;
          -  Able to swallow the study drugs, has no known intolerance to study drugs or&#xD;
             excipients, and able to comply with study requirements.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative pregnancy test at&#xD;
             screening and must agree to use a highly effective birth control method (defined in&#xD;
             protocol) from the time of the first study drug treatment through 45 days after the&#xD;
             last study drug treatment.&#xD;
&#xD;
          -  Male participants must use a condom when having sex from the time of the first study&#xD;
             drug treatment through 105 days after the last study drug treatment. Contraception&#xD;
             should be considered for a non-pregnant female partner of childbearing potential.&#xD;
&#xD;
          -  Male and female participants must agree not to donate sperm or eggs, respectively,&#xD;
             from the first study drug treatment through 105 days and 45 days after the last study&#xD;
             drug treatment, respectively.&#xD;
&#xD;
          -  Female participants may not be breastfeeding at baseline through 45 days after the&#xD;
             last study drug treatment.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL or &gt;= 5.6 mmol/L without transfusion or erythropoietin (EPO)&#xD;
             dependency (within 7 days of assessment)&#xD;
&#xD;
          -  Glomerular filtration rate (by Cockroft-Gault or equivalent estimation) &gt;= 30 mL/min&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 X&#xD;
             ULN OR =&lt; 5 X ULN for participants with liver metastases&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 X upper limit or normal (ULN) OR direct bilirubin =&lt; ULN&#xD;
             for participants with total bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 X ULN unless&#xD;
             participant is receiving anticoagulant therapy, as long as PT or partial&#xD;
             thromboplastin time (PTT) is within therapeutic range of intended use of&#xD;
             anticoagulants&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) =&lt; 1.5 X ULN unless participant is&#xD;
             receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of&#xD;
             intended use of anticoagulants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has not recovered (recovery is defined as Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) version (v)4 grade =&lt; 1 or return to baseline) from the acute&#xD;
             toxicities of previous therapy, except treatment-related alopecia or laboratory&#xD;
             abnormalities otherwise meeting eligibility requirements.&#xD;
&#xD;
          -  Best response of progressive disease per RECIST 1.1 to first-line platinum doublet&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Has received more than 1 line of cytotoxic therapy&#xD;
&#xD;
               -  Prior immunotherapy and targeted therapies (including rovalpituzumab tesirine)&#xD;
                  are allowed.&#xD;
&#xD;
          -  Prior treatment with a PARP inhibitor (not including iniparib) or temozolomide.&#xD;
&#xD;
          -  Use of antineoplastic therapies within 14 days before study treatment initiation.&#xD;
&#xD;
          -  Use of any other investigational agent within 14 days before study treatment&#xD;
             initiation.&#xD;
&#xD;
          -  Received radiation therapy within 14 day before study treatment initiation (single&#xD;
             fraction palliative radiotherapy is allowed without a washout).&#xD;
&#xD;
               -  Prior thoracic irradiation and prophylactic cranial irradiation are allowed.&#xD;
&#xD;
          -  Major surgery within 14 days before study treatment initiation.&#xD;
&#xD;
          -  Diagnosis of myelodysplastic syndrome (MDS).&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
&#xD;
          -  Current or anticipated use of a prohibited P-gp inhibitor or P-gp inducer or BCRP&#xD;
             inhibitors.&#xD;
&#xD;
          -  History of another cancer within 2 years before study treatment initiation, with the&#xD;
             exception of fully treated cancers unlikely to affect the assessment of the study&#xD;
             treatment safety or efficacy including early stage breast, prostate, nonmelanomatous&#xD;
             skin, thyroid, cervix and endometrial cancer.&#xD;
&#xD;
          -  Any condition (concurrent disease, infection, or comorbidity) that interferes with&#xD;
             ability to participate in the study, causes undue risk, or complicates the&#xD;
             interpretation of safety data, in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TRIO-US IST Team</last_name>
    <phone>888-798-0719</phone>
    <email>ISTTeam@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kanamori, MD</last_name>
      <phone>661-622-2206</phone>
    </contact>
    <investigator>
      <last_name>David Kanamori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William E. Lawler, MD</last_name>
      <phone>714-446-5841</phone>
    </contact>
    <investigator>
      <last_name>William E. Lawler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TRIO-US IST Team</last_name>
      <phone>888-798-0719</phone>
    </contact>
    <investigator>
      <last_name>Jonathan W. Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Health, Inc. d/b/a Orlando Health UF Health Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tirrell Tremayne Johnson, MD</last_name>
      <phone>401-648-3800</phone>
    </contact>
    <investigator>
      <last_name>Tirrell Tremayne Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ft. Wayne Medical Oncology and Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Babu, MD</last_name>
      <phone>260-484-8830</phone>
    </contact>
    <investigator>
      <last_name>Sunil Babu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker Dakhil, MD</last_name>
      <phone>316-262-4467</phone>
    </contact>
    <investigator>
      <last_name>Shaker Dakhil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>PARP Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

